Finance - Investment · Founded 1984 · www.religare.com · BSE 532915 · NSE RELIGARE ENT · ISIN INE621H01010
No Notes Added Yet
Business
Religare Enterprises Ltd. (REL) is an India-based diversified financial services company. Its core operations primarily revolve around health insurance and broking services. The company aims to provide a comprehensive suite of financial solutions to retail, HNI, and institutional clients. It makes money primarily through insurance premiums from its health insurance arm (Care Health Insurance), and through brokerage fees, commissions, and advisory services from its broking and wealth management arm (Religare Broking Ltd.). It also has a non-banking financial company (NBFC) subsidiary (Religare Finvest Ltd. - RFL), which is currently undergoing resolution and has been a source of significant historical challenges.
Revenue Mix
Religare Enterprises Ltd. primarily operates through the following segments:
Care Health Insurance (CHI): This is the flagship and most profitable segment, offering health insurance products. It contributes the majority of the company's value and positive earnings.
Religare Broking Ltd.: Provides equity, commodity, and currency broking, depository services, and investment banking services to retail and institutional clients.
Religare Finvest Ltd. (RFL): An NBFC subsidiary. This segment has been under a corrective action plan by the Reserve Bank of India due to past financial irregularities and is undergoing resolution. Its contribution to current positive earnings is limited, and it represents a legacy issue being addressed.
Industry
Religare operates within the competitive Indian financial services sector.
Health Insurance: Care Health Insurance operates in a rapidly growing, but highly competitive, Indian health insurance market. It has established itself as a credible player with a significant market share among standalone health insurers, positioning it well to capitalize on increasing healthcare awareness and costs.
Broking: Religare Broking competes in a fragmented broking industry, facing intense competition from both traditional full-service brokers and new-age discount brokers. It leverages its legacy brand and distribution network to serve its client base.
Overall Positioning: Post its historic promoter issues and restructuring, Religare is now primarily seen as a holding company with a strong health insurance asset, while the broking business maintains a niche, and the NBFC is a legacy issue being resolved.
MOAT
Brand & Trust (Care Health Insurance): Care Health Insurance has built a recognized brand name and trust in the specialized health insurance segment, which is crucial for customer acquisition and retention in an emotional product category like health.
Regulatory Licenses: Ownership of critical financial licenses (insurance, broking, NBFC) provides a barrier to entry for new players, as these require significant capital, compliance, and regulatory approvals.
Distribution Network: REL benefits from an established distribution network for both its health insurance products and broking services across India, facilitating reach and customer acquisition.
Specialization: Care Health Insurance's focus purely on health insurance allows for specialized product development, underwriting expertise, and claims processing efficiency.
Growth Drivers
Rising Health Insurance Penetration: India's low health insurance penetration and increasing awareness of healthcare costs present a significant growth runway for Care Health Insurance.
Increasing Financialization of Savings: A growing economy and higher disposable incomes are driving more individuals to invest in capital markets, benefiting the broking business.
Digital Adoption: Increasing digital adoption in financial services can lead to wider reach, lower customer acquisition costs, and improved operational efficiency across segments.
Resolution of RFL Issues: A successful and timely resolution of the Religare Finvest Ltd. (RFL) legacy issues could remove a significant financial and reputational overhang, unlocking value and potentially freeing up capital.
Strategic Investor Interest: The ongoing interest from institutional investors and potential for new promoter/management control could bring in capital, strategic direction, and improved governance, driving future growth.
Risks
Regulatory & Legal Risks: The financial services industry is highly regulated. Changes in policies by IRDAI (for insurance), SEBI (for broking), and RBI (for NBFC) can impact profitability. Ongoing legal issues related to past promoter fraud and the RFL resolution pose significant risks.
Intense Competition: All segments (health insurance, broking) face fierce competition, which can put pressure on market share and margins.
Economic Downturn: A slowdown in the Indian economy could lead to lower investment activity (impacting broking) and potentially higher claims or lower premium growth in insurance.
Capital Adequacy: Maintaining adequate capital for its insurance and NBFC operations, especially given growth ambitions and past liabilities, is a continuous requirement.
Reputational Risk: The company has faced significant reputational challenges due to past promoter issues. Rebuilding trust and perception among investors and customers is a long-term endeavor.
Management & Ownership
Religare Enterprises Ltd. has undergone significant changes in its management and ownership structure. The original promoters, Malvinder Mohan Singh and Shivinder Mohan Singh, are no longer in control due to legal and financial issues. The company is currently managed by a professional board and management team working towards resolving legacy issues and focusing on core businesses. There is no single promoter group in the traditional sense. However, the Burman Family (promoters of Dabur India Ltd.) has been steadily increasing its stake and is a significant shareholder, indicating potential for a change in control and strategic direction.
Outlook
Religare Enterprises Ltd. presents a mixed outlook. The company's primary asset, Care Health Insurance, is well-positioned in a high-growth sector and continues to deliver strong performance, forming the core value driver. The broking business provides a steady, albeit competitive, revenue stream. The successful resolution of the long-standing issues surrounding Religare Finvest Ltd. (RFL) is critical to fully unlock value and eliminate a significant drag on the company's financial health and valuation. The increasing stake by the Burman Family suggests potential for renewed strategic focus, capital infusion, and improved governance, which could be a catalyst for future growth and a re-rating of the stock. However, the company continues to face inherent risks from intense competition, regulatory scrutiny, and the lingering complexities of its past legal and financial challenges. Its trajectory will largely depend on sustained execution, prudent management, and the timely resolution of legacy matters.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Revenue | 1856 | 1710 | 1952 | 1668 | 2042 | 1872 | 2064 | 2056 | 2467 | 2353 |
| Other Income | 19 | 5 | 19 | 2 | 8 | 5 | 18 | 12 | 6 | 5 |
| Total Income | 1874 | 1714 | 1971 | 1670 | 2050 | 1876 | 2083 | 2068 | 2473 | 2358 |
| Total Expenditure | 1833 | 1653 | 1876 | 1730 | 1805 | 1851 | 2003 | 2151 | 2325 | 2402 |
| Operating Profit | 42 | 62 | 95 | -60 | 245 | 26 | 79 | -83 | 148 | -44 |
| Interest Expense | 18 | 13 | 13 | 5 | 6 | 7 | 10 | 9 | 10 | 15 |
| Depreciation | 17 | 16 | 15 | 14 | 17 | 13 | 12 | 11 | 12 | 18 |
| Profit Before Tax | 236 | 33 | 67 | -79 | 222 | 6 | 57 | -103 | 127 | -77 |
| Provision for Tax | 55 | 6 | -1 | -16 | 71 | -2 | 12 | -27 | 32 | -30 |
| Profit After Tax | 181 | 27 | 69 | -63 | 151 | 8 | 46 | -77 | 96 | -47 |
| Adjustments | -56 | -9 | -17 | 20 | -52 | -10 | -7 | 31 | -13 | 26 |
| Profit After Adjustments | 125 | 18 | 51 | -43 | 98 | -2 | 39 | -45 | 82 | -21 |
| Adjusted Earnings Per Share | 3.8 | 0.5 | 1.6 | -1.3 | 3 | -0.1 | 1.2 | -1.4 | 2.5 | -0.6 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Revenue | 5659 | 4181 | 2524 | 2307 | 2366 | 2493 | 3224 | 4676 | 6235 | 7378 | 8459 | 8940 |
| Other Income | 71 | 69 | 211 | 94 | 42 | 58 | 165 | 504 | 718 | 192 | 201 | 41 |
| Total Income | 5730 | 4250 | 2736 | 2401 | 2408 | 2551 | 3389 | 5181 | 6952 | 7570 | 8660 | 8982 |
| Total Expenditure | 3280 | 2074 | 2842 | 3025 | 2352 | 2256 | 3616 | 4514 | 6551 | 7202 | 8473 | 8881 |
| Operating Profit | 2450 | 2176 | -106 | -624 | 56 | 294 | -227 | 666 | 401 | 368 | 187 | 100 |
| Interest Expense | 1879 | 1840 | 1271 | 854 | 855 | 733 | 750 | 641 | 112 | 63 | 53 | 44 |
| Depreciation | 36 | 31 | 30 | 26 | 61 | 59 | 53 | 56 | 72 | 62 | 47 | 53 |
| Profit Before Tax | 282 | -136 | -1407 | -1504 | -1030 | -497 | -1031 | 3259 | 448 | 243 | 87 | 4 |
| Provision for Tax | 222 | -13 | -227 | -3 | 8 | -20 | 507 | 90 | 100 | 61 | 14 | -13 |
| Profit After Tax | 60 | -123 | -1181 | -1501 | -1038 | -478 | -1539 | 3169 | 347 | 183 | 73 | 18 |
| Adjustments | -108 | -51 | 136 | 214 | 106 | -31 | -5 | -87 | -115 | -58 | 13 | 37 |
| Profit After Adjustments | -48 | -174 | -1045 | -1287 | -932 | -508 | -1544 | 3082 | 233 | 125 | 86 | 55 |
| Adjusted Earnings Per Share | -2.7 | -9.8 | -58.6 | -59.3 | -36.1 | -19.6 | -48.4 | 95.2 | 7.1 | 3.8 | 2.6 | 1.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 22% | 28% | 4% |
| Operating Profit CAGR | -49% | -35% | -9% | -23% |
| PAT CAGR | -60% | -72% | 0% | 2% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -11% | -2% | 5% | -2% |
| ROE Average | 3% | 9% | 124% | 17% |
| ROCE Average | 5% | 12% | 30% | 15% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 3863 | 2753 | 1837 | 833 | 101 | -47 | -982 | 2058 | 2343 | 2515 | 2908 |
| Minority's Interest | 185 | 494 | 418 | 219 | 93 | 345 | 450 | 620 | 831 | 921 | 969 |
| Borrowings | 11858 | 8917 | 0 | 0 | 0 | 3878 | 3740 | 245 | 0 | 0 | 100 |
| Current Liability | 10304 | 8253 | 11607 | 7707 | 6940 | 3378 | 4386 | 2584 | 6146 | 7536 | 10324 |
| Other Liabilities & Provisions | 2216 | 1605 | 732 | 834 | 476 | 614 | 1714 | 2530 | 102 | 155 | 156 |
| Total Liabilities | 28427 | 22022 | 14594 | 9594 | 7611 | 8168 | 9308 | 8036 | 9423 | 11127 | 14457 |
| Loans | 13859 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 607 | 431 | 444 |
| Investments | 1775 | 1146 | 0 | 0 | 0 | 0 | 0 | 0 | 2867 | 7789 | 10024 |
| Fixed Assets | 1785 | 103 | 80 | 83 | 175 | 117 | 127 | 196 | 161 | 145 | 133 |
| Other Loans | 1306 | 1390 | 1905 | 1143 | 504 | 361 | 329 | 330 | 114 | 102 | 99 |
| Other Non Current Assets | 206 | 143 | 45 | 35 | 29 | 189 | 147 | 123 | 160 | 269 | 317 |
| Current Assets | 9496 | 19240 | 12564 | 8333 | 6903 | 7501 | 8705 | 7386 | 5514 | 2391 | 3441 |
| Total Assets | 28427 | 22022 | 14594 | 9594 | 7611 | 8168 | 9308 | 8036 | 9423 | 11127 | 14457 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1025 | 1222 | 1524 | 414 | 119 | 372 | 251 | 1717 | 205 | 201 | 254 |
| Cash Flow from Operating Activities | -2154 | 5871 | 5802 | 3555 | 2433 | 1373 | 1596 | 1506 | 1500 | 1523 | 1820 |
| Cash Flow from Investing Activities | 515 | 2318 | -457 | -31 | -436 | -1181 | -689 | -939 | -1348 | -1185 | -2176 |
| Cash Flow from Financing Activities | 1853 | -7696 | -6455 | -3819 | -1743 | -314 | 559 | -2079 | -156 | -285 | 690 |
| Net Cash Inflow / Outflow | 214 | 492 | -1110 | -295 | 254 | -122 | 1466 | -1512 | -4 | 53 | 334 |
| Closing Cash & Cash Equivalent | 1222 | 1546 | 414 | 119 | 372 | 251 | 1717 | 205 | 201 | 254 | 588 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -2.67 | -9.77 | -58.56 | -59.33 | -36.12 | -19.6 | -48.43 | 95.24 | 7.06 | 3.77 | 2.58 |
| CEPS(Rs) | 5.39 | -5.18 | -64.47 | -68 | -37.85 | -16.15 | -46.58 | 99.67 | 12.71 | 7.4 | 3.61 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 215.2 | 152.81 | 102.91 | 33.42 | 2.63 | -2.66 | -30.95 | 63.52 | 70.9 | 76.05 | 76.42 |
| Net Profit Margin | 1.07 | -2.95 | -46.76 | -65.05 | -43.87 | -19.17 | -47.73 | 67.76 | 5.57 | 2.48 | 0.86 |
| Operating Margin | 38.18 | 40.74 | -5.42 | -28.15 | -7.39 | 9.45 | -8.71 | 83.39 | 8.97 | 4.15 | 1.66 |
| PBT Margin | 4.98 | -3.26 | -55.75 | -65.16 | -43.53 | -19.96 | -31.98 | 69.68 | 7.18 | 3.3 | 1.03 |
| ROA(%) | 0.22 | -0.49 | -6.45 | -12.41 | -12.07 | -6.06 | -17.61 | 36.54 | 3.98 | 1.78 | 0.57 |
| ROE(%) | 1.56 | -3.76 | -51.76 | -117.19 | -261.78 | 0 | 0 | 592.99 | 15.82 | 7.53 | 2.89 |
| ROCE(%) | 9.72 | 8.16 | -0.93 | -6.72 | -2.69 | 4.57 | -6.46 | 117.45 | 20.44 | 11.46 | 4.71 |
| Price/Earnings(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.52 | 29.64 | 62.33 | 78.25 |
| Price/Book(x) | 1.33 | 1.42 | 0.53 | 0.88 | 7.21 | -32.89 | -4.21 | 2.28 | 2.95 | 3.09 | 2.64 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 4.17 | 4.02 | 3.63 | 2.63 | 1.85 | 2.58 | 2.04 | 0.99 | 0.99 | 0.93 | 0.64 |
| EV/Core EBITDA(x) | 9.64 | 7.73 | -86.09 | -9.72 | 78.08 | 21.85 | -28.91 | 6.92 | 15.45 | 18.66 | 28.97 |
| Interest Earned Growth(%) | 3.32 | -26.12 | -39.62 | -8.6 | 2.55 | 5.35 | 29.31 | 45.07 | 33.32 | 18.34 | 14.65 |
| Net Profit Growth | -81.22 | -304.61 | -856.97 | -27.14 | 30.85 | 53.97 | -221.99 | 305.95 | -89.04 | -47.4 | -59.97 |
| EPS Growth(%) | -130.99 | -265.68 | -499.23 | -1.32 | 39.12 | 45.74 | -147.07 | 296.68 | -92.58 | -46.65 | -31.49 |
| Interest Coverage(x) % | 1.15 | 0.93 | -0.11 | -0.76 | -0.2 | 0.32 | -0.37 | 6.08 | 5 | 4.88 | 2.64 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 25.67 | 25.83 | 25.83 | 26.27 | 30.27 | 30.56 |
| FII | 7.91 | 8.49 | 8.01 | 8.04 | 8.25 | 8.1 | 7.8 | 7.61 | 7.85 | 9.64 |
| DII | 8.17 | 10.99 | 13.43 | 13.13 | 11.75 | 11.61 | 10.26 | 9.32 | 8.51 | 8.59 |
| Public | 83.92 | 80.52 | 78.56 | 78.83 | 54.33 | 54.46 | 56.11 | 56.8 | 53.37 | 51.21 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 8.49 | 8.54 | 8.54 | 8.74 | 10.08 | 10.43 |
| FII | 2.61 | 2.8 | 2.64 | 2.66 | 2.73 | 2.68 | 2.58 | 2.53 | 2.61 | 3.29 |
| DII | 2.69 | 3.63 | 4.44 | 4.34 | 3.89 | 3.84 | 3.39 | 3.1 | 2.83 | 2.93 |
| Public | 27.67 | 26.57 | 25.95 | 26.06 | 17.96 | 18.01 | 18.56 | 18.9 | 17.77 | 17.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 32.97 | 33 | 33.03 | 33.06 | 33.07 | 33.07 | 33.08 | 33.27 | 33.29 | 34.12 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | +22% | +28% | +4% |
| Operating Profit CAGR | -49% | -35% | -9% | -23% |
| PAT CAGR | -60% | -72% | — | +2% |
| Share Price CAGR | -11% | -2% | +5% | -2% |
| ROE Average | +3% | +9% | +124% | +17% |
| ROCE Average | +5% | +12% | +30% | +15% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 25.67 | 25.83 | 25.83 | 26.27 | 30.27 | 30.56 |
| FII | 7.91 | 8.49 | 8.01 | 8.04 | 8.25 | 8.1 | 7.8 | 7.61 | 7.85 | 9.64 |
| DII | 8.17 | 10.99 | 13.43 | 13.13 | 11.75 | 11.61 | 10.26 | 9.32 | 8.51 | 8.59 |
| Public | 83.92 | 80.52 | 78.56 | 78.83 | 54.33 | 54.46 | 56.11 | 56.8 | 53.37 | 51.21 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 8.49 | 8.54 | 8.54 | 8.74 | 10.08 | 10.43 |
| FII | 2.61 | 2.8 | 2.64 | 2.66 | 2.73 | 2.68 | 2.58 | 2.53 | 2.61 | 3.29 |
| DII | 2.69 | 3.63 | 4.44 | 4.34 | 3.89 | 3.84 | 3.39 | 3.1 | 2.83 | 2.93 |
| Public | 27.67 | 26.57 | 25.95 | 26.06 | 17.96 | 18.01 | 18.56 | 18.9 | 17.77 | 17.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 32.97 | 33 | 33.03 | 33.06 | 33.07 | 33.07 | 33.08 | 33.27 | 33.29 | 34.12 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.